Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose rituximab for refractory HCV-associated mixed cryoglobulinemia
2008-000086-38Phase 2Active
- Sponsor
- Azienda Ospedaliero-Universitaria Policlinico Umberto I
- Start
- Apr 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in mixed cryoglobulinemia (MC) and cryoglobulinaemia, sponsored by Azienda Ospedaliero-Universitaria Policlinico Umberto I. Primary endpoints: Response rate at 12 weeks, Remission at 6 months and 3 more. Started Apr 2008; status: active.
02
Drugs
rituximab
03
Conditions
mixed cryoglobulinemia (MC)cryoglobulinaemia
Beyond the preview
Go deeper on 2008-000086-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000086-38.